Viavi looks expensive against its cash earnings: at 23x, versus the 11x its industry usually gets, it trades 77% above the high end of a $17.76–$22.60 fair range. That range is 11x next year's cash earnings, give or take 12%, and leans on a forecast 69% above trailing earnings. This is a valuation read only, with no fundamental work. x.com